Tiwari B.P.,Bhabha Atomic Research Center |
Nistala S.,Topiwala National Medical College And B Y L Nair Charitable Hospital |
Patil S.P.,Board of Radiation and Isotope Technology BRIT |
Kalgutkar D.P.,Board of Radiation and Isotope Technology BRIT |
And 3 more authors.
Nuclear Medicine Communications | Year: 2014
The carbon urea breath test (14C-UBT) is a noninvasive technique used to detect Helicobacter pylori infection in patients presenting with dyspeptic symptoms. The present study was undertaken to determine the efficacy of indigenously produced 14C-UBT capsules by the Board of Radiation and Isotope Technology, India. Thirty consecutive patients with dyspeptic symptoms were included in the study. After ingestion of capsules, breath samples were collected in a CO2-trapping solution to which a scintillation cocktail was added. After 24 h, the whole sample was counted in a liquid scintillation counter along with a standard of 14C. The number of disintegrations of 14C per minute in the breath sample was calculated. The results were compared with histopathological reports. Of 30 patients, 19 were positive and 11 were negative on 14C-UBT. Histopathological reports confirmed 27 cases as positive and three as negative for H. pylori. Thus, the results of 14C-UBT were concordant with histopathological results in 22/30 (73.3%) cases. Considering histopathology as the gold standard, the sensitivity, specificity, and positive predictive value of 14C-UBT using indigenously produced capsules were found to be 70.33, 100, and 100%, respectively. On critical analysis of the discordant results, we observed that six patients had undergone H. pylori eradication therapy exactly 4 weeks before the test. When these six patients were excluded from the analysis, the sensitivity, specificity, and positive predictive value were found to be 90.05, 100, and 100%, respectively, which compared well with the values obtained using the standard procedure. The study demonstrates adequate efficacy of the indigenous methodology in newly diagnosed symptomatic patients with acid peptic disorders. The analyses of the results indicate that the test should be preferably employed after the recommended period of 1 month following completion of eradication therapy. © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source
Murhekar V.V.,Board of Radiation and Isotope Technology BRIT |
Mathur A.,Board of Radiation and Isotope Technology BRIT |
Prabhakar G.,Board of Radiation and Isotope Technology BRIT |
Karkhanis B.P.,Board of Radiation and Isotope Technology BRIT |
And 5 more authors.
Journal of Radioanalytical and Nuclear Chemistry | Year: 2014
Board of Radiation and Isotope Technology, India is a manufacturer and supplier of therapeutic doses of the 131I-meta-iodobenzylguanidine to various nuclear medicine centers in India. The therapeutic dosage of radiopharmaceutical involves a single variable dose of >3.7 GBq activity. Since the radiopharmaceutical produced is mainly by isotope exchange, which yields a low specific activity product, the determination of its accurate mass is a critical parameter for its safe administration in patients. In view of this, a suitable high performance liquid chromatography (HPLC) method has been developed for the determination of specific activity with high precision. Also, quantification of stability in terms of the % radiochemical purity of the formulation >370 MBq/mL supplied, under different storage conditions over time was carried out using the developed HPLC method. © Akadémiai Kiadó, Budapest, Hungary 2014. Source